BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29263788)

  • 1. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate.
    Satoh T; Lipton S
    F1000Res; 2017; 6():2138. PubMed ID: 29263788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of: Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs.
    Satoh T; McKercher SR; Lipton SA
    Free Radic Biol Med; 2014 Jan; 66():45-57. PubMed ID: 24262357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
    Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
    FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs.
    Satoh T; McKercher SR; Lipton SA
    Free Radic Biol Med; 2013 Dec; 65():645-657. PubMed ID: 23892355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.
    Brennan MS; Matos MF; Li B; Hronowski X; Gao B; Juhasz P; Rhodes KJ; Scannevin RH
    PLoS One; 2015; 10(3):e0120254. PubMed ID: 25793262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The status of Nrf2-based therapeutics: current perspectives and future prospects.
    Gazaryan IG; Thomas B
    Neural Regen Res; 2016 Nov; 11(11):1708-1711. PubMed ID: 28123399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
    Abed DA; Goldstein M; Albanyan H; Jin H; Hu L
    Acta Pharm Sin B; 2015 Jul; 5(4):285-99. PubMed ID: 26579458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1.
    Satoh T; Kosaka K; Itoh K; Kobayashi A; Yamamoto M; Shimojo Y; Kitajima C; Cui J; Kamins J; Okamoto S; Izumi M; Shirasawa T; Lipton SA
    J Neurochem; 2008 Feb; 104(4):1116-31. PubMed ID: 17995931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
    Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
    Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the modification of Kelch-like ECH-associated protein 1 by different fumarates.
    Qu L; Guo M; Zhang H; Chen X; Wei H; Jiang L; Li J; Chen Z; Dai S; Chen Y
    Biochem Biophys Res Commun; 2022 May; 605():9-15. PubMed ID: 35306364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound.
    Ohnuma T; Nakayama S; Anan E; Nishiyama T; Ogura K; Hiratsuka A
    Toxicol Appl Pharmacol; 2010 Apr; 244(1):27-36. PubMed ID: 20026152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
    Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
    J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
    Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE system.
    Liu Y; Qiu J; Wang Z; You W; Wu L; Ji C; Chen G
    J Neurosurg; 2015 Oct; 123(4):915-23. PubMed ID: 25614941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals.
    Surh YJ; Kundu JK; Na HK
    Planta Med; 2008 Oct; 74(13):1526-39. PubMed ID: 18937164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
    Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
    J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of anti-oxidant Nrf2 signaling by substituted trans stilbenes.
    Deck LM; Whalen LJ; Hunsaker LA; Royer RE; Vander Jagt DL
    Bioorg Med Chem; 2017 Feb; 25(4):1423-1430. PubMed ID: 28126440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway.
    Kobayashi K; Tomiki H; Inaba Y; Ichikawa M; Kim BS; Koh CS
    Int Immunol; 2015 Jul; 27(7):333-44. PubMed ID: 25721871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present).
    Zhou H; Wang Y; You Q; Jiang Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):209-225. PubMed ID: 31922884
    [No Abstract]   [Full Text] [Related]  

  • 20. Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.
    Ma B; Lucas B; Capacci A; Lin EY; Jones JH; Dechantsreiter M; Enyedy I; Marcotte D; Xiao G; Li B; Richter K
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126852. PubMed ID: 31898999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.